Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Renal Cell 11Carcinoma, Hepatocellular 10Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 6Melanoma 4Endometrial Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Adenoid Cystic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Clear Cell Carcinoma 1Non-squamous Non-small-cell Lung Cancer 1NSCLC 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 3Cisplatin 3Carboplatin 3entrectinib 2Radiotherapy, Intensity-Modulated 2Platinum 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab deruxtecan 1luprolide acetate gel depot 1lenvatinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1X-Rays 1Surveys and Questionnaires 1Radiotherapy, Conformal 1Radiosurgery 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1EBC-46 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Salivary Gland Neoplasms × lenvatinib × Clear all
NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
64 enrolled
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡